Policymakers are trying to stave off a potential fuel-supply crunch while refineries look to close. ...

RACINE, Wis. — Microsoft said Thursday that it will spend $4 billion to build a second data center in Wisconsin. The first one will come online in early 2026, with the software company spending $3.3 billion on it.The first Wisconsin data center will house hundreds of thousands of Nvidia chips that are capable of handling artificial intelligence models, Brad Smith, Microsoft's president and vice chair, wrote in a blog post.Cloud infrastructure providers are racing to build capacity to meet the needs of compa ...

Industry Overview - The Canadian cannabis sector is a focal point for investors as it continues to evolve with expanding operations and long-term growth strategies [1][3] - The U.S. cannabis industry has surpassed $33 billion in annual sales, with projections exceeding $50 billion by 2030, indicating significant global opportunities for Canadian companies [1] - Recent developments in U.S. legalization discussions, including potential federal rescheduling of cannabis, could enhance banking access and reduce tax burdens, fostering optimism for both U.S. and Canadian firms [1][2] Company Summaries Cronos Group (CRON) - Cronos Group focuses on research, development, and global distribution, emphasizing branded products and international medical cannabis opportunities rather than a large U.S. dispensary network [4][7] - The company reported revenue of approximately CAD $33.5 million, a 20% year-over-year increase, but also a net loss of about CAD $38.5 million due to foreign-exchange headwinds and investment costs [7] - Cronos has improved gross margins and maintains a strong liquidity position, allowing for strategic flexibility and potential growth in global medical markets [7] SNDL Inc. (SNDL) - SNDL has established one of the largest retail footprints in Canada, operating over 180 retail locations under various banners, while also pursuing investments in the U.S. market [8][10] - The company reported net revenue of approximately CAD $244.8 million, with a gross profit increase of over 16% and positive operating income of around CAD $5 million for the first time in several years [10] - SNDL's strong cash position of over CAD $200 million and no debt on its balance sheet provide financial stability, while its strategy focuses on expanding its retail network and preparing for cross-border opportunities [10] Aurora Cannabis (ACB) - Aurora Cannabis emphasizes medical cannabis exports and global distribution, serving regulated medical markets in Europe and Australia, while shifting away from low-margin recreational cannabis [11][13] - The company reported total net revenue of about CAD $81 million, reflecting nearly 30% growth year-over-year, with medical cannabis sales increasing over 40% to more than CAD $61 million [13] - Aurora's adjusted gross margins improved to roughly 54%, showcasing higher profitability from its medical and international operations, despite challenges from regulatory shifts and competition [13] Investment Considerations - Investors should monitor the financial performance, operational strategies, and regulatory changes affecting Cronos Group, SNDL, and Aurora Cannabis, as each company presents unique opportunities and risks in the evolving cannabis landscape [14]

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.Following the market opening Thursday, the Dow traded down 0.04% to 46,000.59 while the NASDAQ rose 0.49% to 22,370.12. The S&P 500 also rose, gaining, 0.29% to 6,619.34.Check This Out: This Target Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For ThursdayLeading and Lagging SectorsInformation technology shares jumped by 0.8% on Thursday.In trading on Thursday, materials ...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.Following the market opening Thursday, the Dow traded down 0.04% to 46,000.59 while the NASDAQ rose 0.49% to 22,370.12. The S&P 500 also rose, gaining, 0.29% to 6,619.34.Check This Out: This Target Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For ThursdayLeading and Lagging SectorsInformation technology shares jumped by 0.8% on Thursday.In trading on Thursday, materials ...

Finclusion, a new entrant in the UK's motor finance market, has forged a partnership with UK-based fintech company Sikoia. The collaboration aims to enhance the car finance decision-making process by integrating Sikoia's API into Finclusion's operations. The integration will allow customers to provide information while enabling the use of AI-driven document analysis and Open Banking data to verify income and affordability. This is expected to lead to faster and more accurate lending decisions. By adopti ...

Company Overview - Ventas, Inc. (VTR) has a market cap of $30.6 billion and operates a diverse portfolio of approximately 1,400 properties across the U.S., Canada, and the U.K., focusing on the aging population by investing in senior housing communities, medical office buildings, research & innovation centers, and healthcare facilities [1] - As a large-cap stock, Ventas leverages operational expertise, strategic partnerships, and data-driven insights to deliver strong performance and enhance the quality of life for its clients [2] Stock Performance - Shares of Ventas have decreased by 5.6% from their 52-week high of $71.36, but have risen 7.5% over the past three months, outperforming the Real Estate Select Sector SPDR Fund (XLRE) during the same period [3] - Year-to-date, Ventas shares have increased by 14.5%, significantly outpacing XLRE's 3.3% gain, and have gained nearly 5% over the past 52 weeks, while XLRE has dropped by 6.3% [4] Financial Results - Following the Q2 2025 results released on July 30, Ventas shares recovered by 1.1%, reporting normalized FFO of $0.87 per share, which is a 9% year-over-year increase, and revenues of $1.42 billion, reflecting an 18.3% growth [5] - The senior housing operating portfolio (SHOP) showed strong performance with same-store NOI up 13.3% and occupancy increasing by 240 basis points to 87.6% [5] Future Outlook - Ventas has raised its 2025 normalized FFO guidance to a range of $3.41 to $3.46 per share and increased its senior housing investment outlook to $2.0 billion [6] - Despite underperforming compared to rivals like Welltower Inc. (WELL), which has seen a YTD increase of 31.9%, analysts remain bullish on Ventas with a consensus rating of "Strong Buy" and a mean price target of $77.39, indicating a potential upside of 14.9% from current levels [6][7]

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fluor Corporation (“Fluor” or the “Company”) (NYSE: FLR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Fluor Corporation (NYSE: FLR)?Did you purchase your shares between February 18, 2025 and July 31, 2025, inclusive?Did you lose money in y ...

Core Viewpoint - Roche Holding has agreed to acquire 89bio for up to $3.5 billion to enhance its drug pipeline, particularly targeting liver diseases associated with obesity [1][4]. Company Strategy - Roche aims to enter the weight-loss drug market, which is currently dominated by Eli Lilly and Novo Nordisk, and is focusing on developing new treatments and drug combinations for related conditions [2][6]. - The acquisition is part of Roche's strategy to strengthen its position in the cardiovascular space, which is seen as crucial for future growth [3][5]. Financial Details - The deal involves an initial payment of $14.50 per share at closing, with additional performance-based payments of up to $6 per share, representing a significant premium over 89bio's recent closing price of $8.08 [4]. - Following the announcement, shares of 89bio surged by 86% shortly after the U.S. market opened, while Roche's stock remained stable in European trading [4]. Market Potential - The obesity market is expected to become increasingly fragmented and patient-driven, which aligns with Roche's long-term portfolio strategy [6]. - The main asset from 89bio is a drug candidate for metabolic dysfunction-associated steatohepatitis (MASH), currently in late-stage clinical trials, indicating significant potential for future growth [3][6].

Deliveroo CEO Will Shu went from grinding 100-hour weeks on Wall Street to creating a solution to London’s lack of late-night food delivery. More than a decade later, he’s walking away with nearly $250 million after turning his midnight cravings into a $4 billion DoorDash acquisition. From biking orders himself to battling a rocky IPO, Shu’s all-in approach has helped fuel his entrepreneurial mission. For Will Shu, food delivery is personal. As a former investment banker at JPMorgan in London, he was d ...